Cargando…

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

BACKGROUND: Patients with esophageal squamous cell carcinoma (SCC) have limited treatment options. Blocking transforming growth factor-β (TGFβ), which can be overexpressed in these tumors, may enhance responses to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] inhibitors. Bintra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chia-Chi, Doi, Toshihiko, Muro, Kei, Hou, Ming-Mo, Esaki, Taito, Hara, Hiroki, Chung, Hyun Cheol, Helwig, Christoph, Dussault, Isabelle, Osada, Motonobu, Kondo, Shunsuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266718/ https://www.ncbi.nlm.nih.gov/pubmed/33840050 http://dx.doi.org/10.1007/s11523-021-00810-9

Ejemplares similares

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
por: Yoo, Changhoon, et al.
Publicado: (2020)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
por: Tan, Benjamin, et al.
Publicado: (2021)

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1
por: Vugmeyster, Yulia, et al.
Publicado: (2020)

Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety‐Assessment Cohort
por: Doi, Toshihiko, et al.
Publicado: (2020)

Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1
por: Wiggins, Claire J., et al.
Publicado: (2021)

Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma
por: Khasraw, Mustafa, et al.
Publicado: (2021)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
por: Strauss, Julius, et al.
Publicado: (2020)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
por: Barlesi, Fabrice, et al.
Publicado: (2022)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
por: Cho, Byoung Chul, et al.
Publicado: (2020)

Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
por: Lan, Yan, et al.
Publicado: (2022)

Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
por: Ozawa, Yohei, et al.
Publicado: (2021)

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
por: Spira, Alexander, et al.
Publicado: (2022)

Correction: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Publicado: (2020)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

Erratum: The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
Publicado: (2020)

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer
por: Spira, Alexander, et al.
Publicado: (2022)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer
por: Morris, Van K., et al.
Publicado: (2022)

NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
por: Xu, Chunxiao, et al.
Publicado: (2021)

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
por: Yoo, Changhoon, et al.
Publicado: (2023)

Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial
por: Chiang, Chi Leung, et al.
Publicado: (2023)

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
por: Doi, Toshihiko, et al.
Publicado: (2018)

A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
por: Liu, Han, et al.
Publicado: (2023)

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
por: Tolcher, Anthony W, et al.
Publicado: (2023)

A bifunctional cerium phosphate catalyst for chemoselective acetalization
por: Kanai, Shunsuke, et al.
Publicado: (2017)

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2016)

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy
por: Wu, Zhen-Hua, et al.
Publicado: (2022)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
por: Kawakami, Hisato, et al.
Publicado: (2021)

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2013)

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
por: Kojima, Takashi, et al.
Publicado: (2018)

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
por: Esaki, Taito, et al.
Publicado: (2019)

Cerebral infarction following administration of andexanet alfa for anticoagulant reversal in a patient with traumatic acute subdural hematoma
por: Nagai, Arata, et al.
Publicado: (2023)

ATLAS/ALFA detector at LHC tunnel Point 1
por: Suykerbuyk, Ronaldus
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fdpm4hra706i0b2uu70g35se1a